Sudeep Pharma Share Price Target 2027: Is Rs 1,338 Realistic? Bull Case Points to Rs 1,620
- November 6, 2026
- Posted by: Kunal Singla
- Category: Market
Sudeep Pharma share price Rs 1,161.90 (6 November 2026). Base target Rs 1,338, bull Rs 1,620, downside risk Rs 953. PE 71.3. 52W range Rs 524.05 to Rs 1,378.00.
Quick Answer
The Sudeep Pharma share price target for 2027 is Rs 1,338, about 15.2% above the current price of Rs 1,161.90. The bull case is Rs 1,620, and the downside risk level, which is not a target, is Rs 953. The base case assumes earnings per share grow 12.3% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 71.3. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Sudeep Pharma target price for 2027 should start with where the stock sits today. At Rs 1,161.90 on 6 November 2026, it is 15.7% below its 52-week high of Rs 1,378.00 and 121.7% above its 52-week low of Rs 524.05. That range spans 163% from low to high, so the entry point matters as much as the Sudeep Pharma price forecast itself.
This article builds the Sudeep Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Sudeep Pharma Stock Analysis: Company Overview and Key Stats
Sudeep Pharma (NSE: SUDEEPPHRM) has a market capitalisation of Rs 13,449 crore. In FY26 it reported revenue of Rs 670.84 crore and net profit of Rs 174.28 crore. The table collects the figures the Sudeep Pharma share price target is built on.
| Metric | Value |
|---|---|
| Company | Sudeep Pharma |
| NSE Ticker | SUDEEPPHRM |
| CMP (6 November 2026) | Rs 1,161.90 |
| 52-Week High | Rs 1,378.00 |
| 52-Week Low | Rs 524.05 |
| Market Cap | Rs 13,449 crore |
| PE Ratio (TTM) | 71.30 |
| Industry PE | 33.07 |
| Price to Book | 14.05 |
| Return on Equity | 19.67% |
| Debt to Equity | 0.20 |
| EPS (TTM) | Rs 16.70 |
| Dividend Yield | 0.00% |
| 12-Month Base Target | Rs 1,338 |
| Bull Case | Rs 1,620 |
| Downside Risk Level (not a target) | Rs 953 |
Why Is Sudeep Pharma Share Price Target Set at Rs 1,338 for 2027?
The arithmetic is short. Trailing EPS of Rs 16.70 grown for one year gives a forward EPS estimate of Rs 18.76, and multiplying it by the unchanged PE of 71.30 gives the Rs 1,338 base-case Sudeep Pharma stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Sudeep Pharma Target Price: Five Years of Results
Sudeep Pharma grew revenue from Rs 350.40 crore in FY22 to Rs 670.84 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew faster, from Rs 50.17 crore to Rs 174.28 crore (36.5% a year), which shows margin gains did part of the work and not just higher sales.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 350.40 | 50.17 | 356.01 | 0.00 |
| FY23 | 438.26 | 62.32 | 5.74 | 0.00 |
| FY24 | 465.38 | 133.19 | 12.28 | 0.00 |
| FY25 | 511.33 | 138.73 | 12.79 | 0.00 |
| FY26 | 670.84 | 174.28 | 15.50 | 0.00 |
FY26 revenue growth was 31.2%, faster than the four-year average of 17.6%, and net profit moved up 25.6%. EPS rose from Rs 12.28 in FY24 to Rs 15.50 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Sudeep Pharma converted 26.0% of FY26 revenue into net profit, against 27.1% in FY25, within a five-year range of 14.2% to 28.6%. EBITDA margin was 37.3% in FY26 versus 39.0% in FY25.
In the September 2026 quarter, revenue was Rs 202.68 crore, up 17.3% from the same quarter a year earlier, while net profit of Rs 51.81 crore was up 10.8%. EBITDA came in at Rs 79.23 crore, up 20.7% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.20, and shareholders’ equity grew from Rs 163.34 crore in FY22 to Rs 898.09 crore in FY26. Operating cash flow in FY26 was Rs 69.55 crore against capital expenditure of Rs 118.15 crore, leaving negative free cash flow of Rs 48.60 crore. In FY25 free cash flow was negative at Rs 15.50 crore.
Valuation Check for the Sudeep Pharma Stock Target: PE, Price to Book and ROE
At a PE of 71.30 against an industry PE of 33.07, Sudeep Pharma trades at a premium to its industry. Price to book is 14.05 on a book value of Rs 84.76 per share, and return on equity is 19.67%. A PE of 71.30 equals an earnings yield of 1.4%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.00%.
Shareholding Pattern and Institutional Holding
Promoters held 76.15% of Sudeep Pharma in September 2026, and promoter holding has stayed near 76.15% since November 2025. Foreign institutional investors (FII) held 2.93% and domestic institutions (DII) held 14.05%, which puts total institutional holding at 16.98%. FII holding rose from 1.54% in November 2025 to 2.93% in September 2026. Public shareholders own the remaining 6.87%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Sudeep Pharma Share Price Targets for the Short Term and 12 Months
Short Term Sudeep Pharma Stock Target Levels: Technical Setup
At Rs 1,161.90 on 6 November 2026, Sudeep Pharma trades above its 50-day simple moving average of Rs 1,136.72 and above its 200-day exponential moving average of Rs 918.80. The 14-day RSI reads 68.4, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 1,378.00 (52-week high) and the nearest support is Rs 1,136.72 (50-day simple moving average). A sustained move above Rs 1,378.00 would improve the short-term setup, while a close below Rs 1,136.72 would shift attention to the next support.
12 Month Sudeep Pharma Target Price for 2027
The 12-month target of Rs 1,338 means a move of 15.2% up from Rs 1,161.90 over the next 12 months. It would still leave the stock 2.9% below its 52-week high of Rs 1,378.00. Anyone checking the Sudeep Pharma share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Sudeep Pharma Target Price
| EPS Growth | PE 57.04 | PE 71.30 | PE 81.99 |
|---|---|---|---|
| 0.0% (EPS Rs 16.70) | Rs 953 | Rs 1,191 | Rs 1,369 |
| 12.3% (EPS Rs 18.76) | Rs 1,070 | Rs 1,338 | Rs 1,538 |
| 18.3% (EPS Rs 19.76) | Rs 1,127 | Rs 1,409 | Rs 1,620 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Sudeep Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Sudeep Pharma Stock Target in 2027
Bull Case Rs 1,620
The bull case Sudeep Pharma price target needs EPS growth of 18.3%, which lifts forward EPS to Rs 19.76, and a PE multiple that rises 15% to 81.99. That gives Rs 1,620, 39.4% above the current price and above the 52-week high of Rs 1,378.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 953
The downside risk level is not a target. It assumes EPS stays flat at Rs 16.70 and the PE falls 20% to 57.04. That gives Rs 953, 18.0% below the current price and above the 52-week low of Rs 524.05.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 18.3% | 81.99 | Rs 1,620 | +39.4% |
| Base Case | 12.3% | 71.30 | Rs 1,338 | +15.2% |
| Downside Risk | 0.0% | 57.04 | Rs 953 | -18.0% |
Key Risks to the Sudeep Pharma Target Price for 2027
Growth Slowdown Risk for the Sudeep Pharma Price Target
Revenue in the September 2026 quarter was up 17.3% year on year, and FY26 revenue growth was 31.2%. If growth slows from here, the EPS estimate behind the Sudeep Pharma stock target will need revising.
Liquidity and Size Risk
Sudeep Pharma has a market capitalisation of Rs 13,449 crore. Institutional holding is 16.98%, and promoters hold 76.15%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 26.0% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 71.30 versus an industry PE of 33.07, a de-rating toward the downside-risk PE of 57.04 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 68.4 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.
How to Invest in Sudeep Pharma
Start with the live price and volume. Any Sudeep Pharma share price target is only as current as the data behind it, and the data here is as of 6 November 2026, so refresh the Rs 1,161.90 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Sudeep Pharma’s PE, ROE, debt and shareholding in one place.
Check Sudeep Pharma fundamentals on the Univest Screener
Then compare the three Sudeep Pharma target price scenarios with your own view. If you expect EPS growth below 12.3%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Sudeep Pharma live price and get daily stock recommendations.
Conclusion
The Sudeep Pharma share price target for 2027 is Rs 1,338 in the base case, with Rs 1,620 as the bull case. The support for that view is arithmetic you can check: EPS grew 12.3% a year over FY24 to FY26, and the stock trades at a PE of 71.30. The risks are equally concrete, including a PE of 71.30 that sits above the industry PE of 33.07 and a downside scenario that cuts the price 18% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Sudeep Pharma Share Price Target 2027
What is the Sudeep Pharma share price target for 2027?
Ans. The base-case Sudeep Pharma share price target for 2027 is Rs 1,338, which is 15.2% above the price of Rs 1,161.90 on 6 November 2026. The bull case is Rs 1,620 and the downside risk level, which is not a target, is Rs 953. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Sudeep Pharma share price today?
Ans. As of 6 November 2026, 9:49 AM IST, Sudeep Pharma (NSE: SUDEEPPHRM) trades at Rs 1,161.90, down 2.39% on the day. That is 15.7% below the 52-week high of Rs 1,378.00 and 121.7% above the 52-week low of Rs 524.05. The market capitalisation of Rs 13,449 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Sudeep Pharma a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 12.3% a year over FY24 to FY26 and the base case implies 15.2% upside; on the cautious side, the PE of 71.30 is above the industry PE of 33.07, and the downside risk level of Rs 953 is 18% below the current price. Whether Sudeep Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Sudeep Pharma shares?
Ans. The bull case in the Sudeep Pharma share price target for 2027 is Rs 1,620, which assumes 18.3% EPS growth and a PE of 81.99, a 15% re-rating from today’s multiple. That is 39.4% above the current price and above the 52-week high of Rs 1,378.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 953, which assumes flat EPS and a PE of 57.04, 20% lower than today. It sits 18.0% below the current price and above the 52-week low of Rs 524.05, and it marks a risk to watch, not a target.
What are the main risks to the Sudeep Pharma price target?
Ans. Four risks matter most for the Sudeep Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 13,449 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 57.04 would cut the price even if earnings hold.
What is the PE ratio of Sudeep Pharma and how does it compare with the industry?
Ans. The PE ratio of Sudeep Pharma is 71.30, against an industry PE of 33.07, which is a premium to the industry. Price to book is 14.05 and return on equity is 19.67%, and the PE equals an earnings yield of 1.4%. The base case holds the PE unchanged, so the Sudeep Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Sudeep Pharma, and what is the promoter holding?
Ans. Promoters held 76.15% of Sudeep Pharma in September 2026. FII held 2.93%, DII held 14.05% and the public held 6.87%. Together the two institutional groups hold 16.98%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Sudeep Pharma’s latest quarterly results?
Ans. In the September 2026 quarter, Sudeep Pharma reported revenue of Rs 202.68 crore (up 17.3% year on year) and net profit of Rs 51.81 crore (up 10.8%). For comparison, FY26 full-year revenue growth was 31.2% and net profit moved up 25.6%. Each new quarter either supports or weakens the EPS growth of 12.3% assumed in the base case.
